Abstract 130P
Background
In carcinoma esophagus patients where large volumes of lymphocyte producing organs and organs with circulating lymphocytes are exposed to radiation field, Radiation induced lymphopenia (RIL) is quite profound. Absolute Lymphocyte Count (ALC) has been postulated to have a crucial impact on treatment outcomes.In this study, dosimetric analysis on the organs at risk (OARs) for lymphopenia and its effect on pathological complete response (PCR) was assessed.
Methods
Carcinoma Esophagus patients who underwent neoadjuvant chemo-radiotherapy(NACT-RT) and definitive surgery from December 2018 to March 2021 were studied retrospectively. Data collected included baseline and weekly ALC, PCR on histopathology, mean dose (Dmean) and volume based dosimetry of the OARs for lymphopenia (thoracic vertebrae, bilateral lungs, liver, heart and spleen) and the effective dose to the circulating lymphocytes (EDIC), calculated using the formulae 0.12 (Dmean lung) + 0.08 (Dmean heart) + [0.45+ 0.35x 0.85(no of fractions/45ˆ1/2] Dmean body. PCR rates were correlated with ALC using Spearman’s correlation. Dosimetric parameters and EDIC was correlated with ALC using Pearson’s correlation test (p value<0.05).
Results
33 patient’s data who were eligible for the study was analysed. On Pearson’s correlation test the thoracic vertebrae Dmean (p-0.008) and V15 (p-0.012), liver Dmean (p-0.034) and V20 (p-0.038), heart Dmean (p-0.013) and V15 (p-0.022), spleen Dmean (p-0.040) were found to have significant correlation with ALC nadir. The mean EDIC was 6.21 (SD±5). No significant correlation between EDIC and ALC nadir was identified. 5% of patients did not achieve PCR at surgery. Spearman’s correlation test did not show a significant correlation between PCR and ALC nadir.
Conclusions
RIL has been demonstrated to have a negative impact on treatment outcomes. In our study, we discovered that dosimetric parameters of Dmean and volume based analysis of the OARs for lymphopenia were strongly correlated with ALC Nadir. Statistically significant correlation between ALC nadir and PCR rates was not seen. A larger multicentric study with a large number of patients, however, may be required to statistically prove our hypothesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Presenter: Kazuaki Harada
Session: Poster viewing 02
100P - A prospective single arm study evaluating the outcome of neoadjuvant chemotherapy in locally advanced/border line resectable gall bladder cancer
Presenter: Pulkit Nag
Session: Poster viewing 02
101P - Cachexia index and sarcopenia in patients with advanced gastrointestinal cancer treated with chemotherapy during exercise intervention
Presenter: Song Ee Park
Session: Poster viewing 02
102P - A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Presenter: Caiyun Nie
Session: Poster viewing 02
103P - Concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 02
104P - A multi-institutional epidemiological and oncological profile of gastrointestinal stromal tumors in the Lebanese population
Presenter: Mohamad Hadi El Charif
Session: Poster viewing 02
105P - The efficacy of nivolumab monotherapy for advanced gastric cancer depends on the HER2 status
Presenter: Yuichiro Nishibori
Session: Poster viewing 02
106P - Clinicopathologic and prognostic significance of FBXL5 expression in hepatocellular carcinoma
Presenter: Yoon Ah Cho
Session: Poster viewing 02
107P - Preliminary result of anatomical hepatectomy on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma
Presenter: Xiaozhun Huang
Session: Poster viewing 02